Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Appointed director
CC transcript

Synaptogenix, Inc. (SNPX) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/22/2022 8-K Quarterly results
11/18/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Certificate of Designations",
"Form of Warrant",
"Form of Purchase Agreement",
"Form of Registration Rights Agreement",
"Engagement Letter, by and between Synaptogenix, Inc. and Katalyst Securities LLC",
"Press Release"
08/16/2022 8-K Quarterly results
10/01/2021 8-K Quarterly results
07/16/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/21/2021 8-K Other Events
06/16/2021 8-K Quarterly results
04/30/2021 8-K Financial Statements and Exhibits
Docs: "The unaudited pro forma consolidated balance sheet of the Company as of December 31, 2020"
04/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan"
02/17/2021 8-K Quarterly results
01/22/2021 8-K Quarterly results
01/19/2021 8-K Quarterly results
12/16/2020 8-K Conference call transcript
Docs: "Script of Synaptogenix, Inc. conference call held on December 15, 2020"
12/10/2020 8-K Appointed a new director
Docs: "Amended and Restated Articles of Incorporation of Synaptogenix, Inc.",
"Bylaws of Synaptogenix, Inc",
"Separation and Distribution Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"Tax Matters Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"SEPARATION AGREEMENT",
"Dr. Alan J. Tuchman",
"SYNAPTOGENIX, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS.",
"STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS",
"Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's disease and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy